AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients

Go back to AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

January 21, 2021 8:00 AM EST

DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AzurRx or the Company) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the first two patients have been dosed in the Phase 2b OPTION 2 extension study of MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

The company recently announced an additional study arm in the Phase 2b OPTION 2 study utilizing immediate release capsules in efforts to identify the optimal dose and delivery method... More